Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

November 18, 2021

Study Completion Date

November 18, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin Degludec/Insulin Aspart

All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Trial Locations (1)

00000

Novo Nordisk Investigational Site, Beirut, Hamra

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY